

Steven C Clifford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6498362/publications.pdf>

Version: 2024-02-01

58
papers

12,127
citations

101543

36
h-index

144013

57
g-index

61
all docs

61
docs citations

61
times ranked

8549
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular subgroups of medulloblastoma: the current consensus. <i>Acta Neuropathologica</i> , 2012, 123, 465-472.	7.7	1,536
2	Medulloblastoma Comprises Four Distinct Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 1408-1414.	1.6	1,131
3	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. <i>Acta Neuropathologica</i> , 2012, 123, 473-484.	7.7	863
4	Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105.	27.8	765
5	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
6	Subtypes of medulloblastoma have distinct developmental origins. <i>Nature</i> , 2010, 468, 1095-1099.	27.8	710
7	Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features. <i>PLoS ONE</i> , 2008, 3, e3088.	2.5	606
8	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	7.7	478
9	Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. <i>Acta Neuropathologica</i> , 2011, 121, 381-396.	7.7	474
10	β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. <i>Journal of Clinical Oncology</i> , 2005, 23, 7951-7957.	1.6	411
11	Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. <i>Lancet Oncology</i> , The, 2017, 18, 958-971.	10.7	384
12	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	1.6	381
13	Medulloblastoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 11.	30.5	376
14	Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3187-3193.	1.6	270
15	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
16	Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables. <i>Journal of Clinical Oncology</i> , 2011, 29, 1400-1407.	1.6	263
17	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
18	Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis. <i>Cell Cycle</i> , 2006, 5, 2666-2670.	2.6	247

#	ARTICLE	IF	CITATIONS
19	Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients. <i>Clinical Cancer Research</i> , 2004, 10, 5482-5493.	7.0	198
20	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. <i>Acta Neuropathologica</i> , 2019, 138, 309-326.	7.7	180
21	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. <i>Cancer Cell</i> , 2015, 27, 72-84.	16.8	165
22	Nodule Formation and Desmoplasia in Medulloblastomas—Defining the Nodular/Desmoplastic Variant and Its Biological Behavior. <i>Brain Pathology</i> , 2007, 17, 151-164.	4.1	134
23	DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. <i>Acta Neuropathologica</i> , 2013, 125, 359-371.	7.7	133
24	Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. <i>Journal of Neuro-Oncology</i> , 2016, 129, 515-524.	2.9	99
25	The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. <i>British Journal of Neurosurgery</i> , 2009, 23, 364-375.	0.8	87
26	MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 501-513.	7.7	87
27	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. <i>Nature Communications</i> , 2020, 11, 4324.	12.8	75
28	Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1602-1616.	10.7	67
29	The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. <i>Molecular Brain Research</i> , 2004, 121, 137-140.	2.3	62
30	EANO—EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology</i> , The, 2019, 20, e715-e728.	10.7	56
31	DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 121-130.	5.6	55
32	Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial. <i>Oncotarget</i> , 2015, 6, 38827-38839.	1.8	51
33	TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours. <i>Acta Neuropathologica</i> , 2014, 127, 307-309.	7.7	49
34	TAp73 is a marker of glutamine addiction in medulloblastoma. <i>Genes and Development</i> , 2017, 31, 1738-1753.	5.9	49
35	Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 865-874.	5.6	48
36	Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 47-60.	2.8	43

#	ARTICLE	IF	CITATIONS
37	Increased <i>mdr1</i> gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay. <i>British Journal of Cancer</i> , 1994, 69, 680-686.	6.4	32
38	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. <i>Neuro-Oncology</i> , 2022, 24, 153-165.	1.2	28
39	Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. <i>British Journal of Cancer</i> , 1996, 73, 659-666.	6.4	23
40	The AHR pathway represses TGF β ² -SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastoma. <i>Scientific Reports</i> , 2020, 10, 148.	3.3	22
41	Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures. <i>Scientific Reports</i> , 2017, 7, 13421.	3.3	21
42	Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation. <i>Nature Communications</i> , 2021, 12, 2148.	12.8	20
43	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. <i>Oncotarget</i> , 2017, 8, 112036-112050.	1.8	16
44	SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma. <i>Cancers</i> , 2021, 13, 6077.	3.7	16
45	Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. <i>Cancers</i> , 2022, 14, 374.	3.7	16
46	Combining multi-site magnetic resonance imaging with machine learning predicts survival in pediatric brain tumors. <i>Scientific Reports</i> , 2021, 11, 18897.	3.3	14
47	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial. <i>Advances in Radiation Oncology</i> , 2020, 5, 1158-1169.	1.2	13
48	The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 236-250.	3.2	12
49	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. <i>Cancers</i> , 2022, 14, 126.	3.7	12
50	Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors. <i>Acta Neuropathologica</i> , 2014, 128, 151-153.	7.7	10
51	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. <i>American Journal of Neuroradiology</i> , 2019, 40, 1811-1817.	2.4	9
52	VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells. <i>Communications Biology</i> , 2020, 3, 579.	4.4	9
53	Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 736-747.	3.2	9
54	Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma. , 2021, 228, 107828.		7

#	ARTICLE	IF	CITATIONS
55	Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation. <i>Cell Death and Differentiation</i> , 2022, 29, 1955-1969.	11.2	6
56	Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development. <i>Acta Neuropathologica</i> , 2022, 144, 565-578.	7.7	4
57	Effects of the growth pattern of medulloblastoma on short-term neurological impairments after surgery: results from the prospective multicenter HIT-SIOP PNET 4 study. <i>Journal of Neurosurgery: Pediatrics</i> , 2020, 25, 425-433.	1.3	2
58	Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta-adrenergic receptors in medulloblastoma. <i>EBioMedicine</i> , 2022, 82, 104149.	6.1	2